Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: Results of a prospective, randomized, controlled study in critically ill patients

Critical Care Medicine

Volumn 24, Issue 8, 1996, Pages 1311-1315

  Sorkine, Patrick ^a,b   Nagar, Hagit ^a,b   Weinbroum, Avi ^a,b   Setton, Arick ^a,b   Israitel, Evjeni ^a,b   Scarlatt, Alexander ^a,b   Silbiger, Aviel ^a,b   Rudick, Valery ^a,b   Kluger, Yoram ^a,b   Halpern, Pinchas ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

amphotericin B; Candida sepsis; critically ill patients; drug reactions; fungal infections; lipid emulsions; pharmacology; renal failure; thrombocytopenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; GLUCOSE; INTRALIPID; LIPID EMULSION;

ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; DRUG TOLERANCE; FEMALE; FEVER; HUMAN; HYPOTENSION; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RIGOR; THROMBOCYTOPENIA;

EID: 9344255433     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199608000-00007     Document Type: Article

References (21)

1. Perfect JR, Pickard WW, Hunt DL, et al: The use of amphotericin B in nosocomial fungal infection. Rev Infect Dis 1991; 13:474-479
2. Gallis HA, Drew RH, Packard WW: Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329
3. Chia J, McManus E: In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations. Antimicrob Agents Chemother 1990; 34: 906-908
4. Giglioti F, Shenep JL, Lott L, et al: Induction of prostaglandin synthesis is the mechanism responsible for the chills and fever produced by infusion of amphotericin B. J Infect Dis 1987; 156:784-789
5. Butler WT, Bennett JE, Alling DW, et al: Nephrotoxicity of amphotericin B. Early and late effects in 81 patients. Ann Intern Med 1964; 61:175-187
6. Caillot D, Reny E, Solary E, et al: A controlled trial of amphotericin B infused in dextrose or in intralipids in patients with hematological malignancies. J Antimicrob Chemother 1994; 33: 603-613
7. Chavanet PY, Garry I, Charlier N, et al: Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992; 40:507-512
8. Kirsh R, Goldstein R, Tarloff J, et al: An emulsion formulation of amphotericin B improves therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988; 158:1065-1070
9. Bodey G, Bueltmann B, Duguid W, et al: Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:99-109
10. Sabra R, Branch RA: Amphotericin B nephrotoxicity. Drug Saf 1990; 5:94-108
11. Kaloyanides GJ: Antibiotic-related nephrotoxicity. Nephrol Dial Transplant 1994; 9(Suppl 4):130-134
12. Gary-Bobo CM: Polyene-sterol interaction and selective toxicity. Biochimie 1989; 71:37-47
13. Joly V, Saint Pierre-Chazalet M, Saint-Julien L, et al: Inhibiting cholesterol synthesis reduces the binding and toxicity of amphotericin B against rabbit renal tubular cells in primary culture. J Infect Dis 1992; 65:337-343
14. Allardyce DB: Cholestasis cause by lipid emulsion. Surg Gynecol Obstet 1982; 154:641-647
15. Goulet O, Girot R, Maier-Redelsperger M, et al: Hematologic disorders following prolonged use of intravenous fat emulsions in children. JPEN 1986; 10: 284-288
16. Clayton PT, Bowron A, Mills KA, et al: Phytosterolemia in children with parenteral nutrition-associated cholestatic liver disease. Gastroenterology 1993; 105:1806-1813
17. Barwicz J, Gareau R, Audet A, et al: Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems. Biochem Biophys Res Commun 1991; 181:722-728
18. Perkins WR, Minchey SR, Boni LT, et al: Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992; 1107:271-282
19. Wasan KM, Morton RE, Rosenblum MG, et al: Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer protein. J Pharm Sci 1994; 83:1006-1010
20. Brajburg J, Powderly WG, Kobayashi GS, et al: Amphotericin B: Delivery systems. Antimicrob Agents Chemother 1990; 34:381-384
21. Tollemar J, Ringden O, Tyden G: Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin Transplant 1990; 4:167-175